Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods.

Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, Sharples L.

Med Decis Making. 2017 May;37(4):377-390. doi: 10.1177/0272989X16639900. Epub 2016 Jul 10.

2.

Modeling rheumatoid arthritis using different techniques - a review of model construction and results.

Scholz S, Mittendorf T.

Health Econ Rev. 2014 Dec;4(1):18. doi: 10.1186/s13561-014-0018-2. Epub 2014 Sep 16.

3.

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.

Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M.

PLoS One. 2015 Mar 17;10(3):e0119683. doi: 10.1371/journal.pone.0119683. eCollection 2015. Review.

4.

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC, Luqmani R.

Pharmacoeconomics. 2014 Dec;32(12):1171-83. doi: 10.1007/s40273-014-0189-z.

5.

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.

Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, Dejonckheere F.

Pharmacoeconomics. 2014 Aug;32(8):775-87. doi: 10.1007/s40273-014-0165-7.

6.

Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.

Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS.

J Natl Cancer Inst. 2013 Jun 5;105(11):774-81. doi: 10.1093/jnci/djt096. Epub 2013 May 3.

7.

Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.

Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, Lu LJ.

PLoS One. 2012;7(10):e47373. doi: 10.1371/journal.pone.0047373. Epub 2012 Oct 9.

8.

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Aragão F, Vera J, Vaz Pinto I.

PLoS One. 2012;7(9):e44774. doi: 10.1371/journal.pone.0044774. Epub 2012 Sep 17.

9.

An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity.

Miners A, Harris J, Felix L, Murray E, Michie S, Edwards P.

BMC Health Serv Res. 2012 Jul 7;12:190. doi: 10.1186/1472-6963-12-190.

10.

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

Hallinen TA, Soini EJ, Eklund K, Puolakka K.

Rheumatology (Oxford). 2010 Apr;49(4):767-77. doi: 10.1093/rheumatology/kep425. Epub 2010 Jan 25.

11.

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Lunt M; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2009 Oct;48(10):1323-7. doi: 10.1093/rheumatology/kep242. Epub 2009 Aug 25.

12.

Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?

Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR.

Health Qual Life Outcomes. 2008 Jul 14;6:51. doi: 10.1186/1477-7525-6-51.

13.

Thoughts on health economics in rheumatoid arthritis.

Kobelt G.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii35-9. Review.

14.

Can discrete event simulation be of use in modelling major depression?

Le Lay A, Despiegel N, François C, Duru G.

Cost Eff Resour Alloc. 2006 Dec 5;4:19.

Supplemental Content

Support Center